Objective To explore the effectiveness and safety of Jinyinhua Liquid（金银花口服液） at different dosage combined with conventional Western medicine for treating common type of coronavirus disease 2019（COVID-19）. Methods In a multicenter trial design

300 cases of COVID-19 were randomly divided into control group（conventional treatment: lopinavir-ritonavir

interferon α2 a

etc.）

60 ml Jinyinhua Liquid group（conventional treatment plus oral Jinyinhua Liquid

60 ml each time

3 times daily）

and 120 ml Jinyinhua Liquid group（conventional treatment plus oral Jinyinhua Liquid

120 ml each time

3 times daily）

with 100 cases in each group. The duration of treatment lasted 10 days. The outcomes included negative conversion rate of nucleic acid in the respiratory tract samples

the chest CT score

hospitalization days

time to negative conversion of nucleic acid

aggravation and progression rate

adverse events

and biochemical indicators. Results After treatment

the negative conversion rate of nucleic acid in the control group

60 ml and 120 ml Jinyinhua Liquid group were 67.6%（48/71 cases）

78.0%（46/59 cases） and 78.9%（45/57 cases）

respectively

with no statistically significant between groups（P>0.05）. CT score of the left lung in the control group was not significantly different from that before treatment（P>0.05）

and CT scores significantly decreased after treatment when compared to those before treatment（P<0.05）; compared to the control group

120 ml Jinyinhua Liquid group had significantly lower CT score of right lungs（P<0.05）. The hospitalization duration and time to negative conversion of nucleic acid were significantly shortened in 60 ml and 120 ml Jinyinhua Liquid group compared to the control group（P<0.01）. There were no cases progressing to severe cases in both Jinyinhua Liquid groups

while there were three severe cases（4.22%） in control group. Conclusion Jinyinhua Liquid can better improve the lung lesions and shorten the hospitalization duration and the time to negative conversion of nucleic acid

and dosage of 120 ml per time has a more obvious effect on lung repair in moderate cases of COVID-19.